Basic Information
Avidicure is pioneering a novel dual-agonist, multifunctional, and affinity-engineered antibody modality, “AVC-Boosters,” designed to safely deliver targeted and potent monotherapies with broad applicability in oncology.
Avidicure DEV.
Netherlands
less than 15 people
January 01, 2022
--